RBC Capital Reiterates Outperform on Viracta Therapeutics, Maintains $8 Price Target
RBC Capital analyst Gregory Renza reiterates Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $8 price target.
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Viracta Therapeutics Announced First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting; Said Cash, Cash Equivalents, And Investments Of Over $90M At Year-end 2022 Provide Anticipated Runway Into Late 2024
Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced new clinical data from the Phase 1b/2 trial of Nana-val in patients with EBV+ R/M NPC and other EBV+ solid tumors and outlined its key 2023 clinical objectives.
Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
79 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.